Key papers in Pharmacology
Pofolia’s corpus holds 65 papers from the Pharmacology subfield (2012–2023). The list below starts with the most cited.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”.
Cognitive Therapy for Depression
PsycEXTRA Dataset · 2012 · 9,720 citations
Cognitive therapy (CT) for depression shows acute effects comparable to medication but offers enduring benefits after treatment cessation.
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Journal of Natural Products · 2020 · Q1 · FWCI 476.48 · 6,724 citations · Open access
Natural products and their synthetic variations continue to be a vital source for new drug discovery, contributing significantly to approved therapeutic agents, particularly in cancer treatment.
Natural Products as Sources of New Drugs from 1981 to 2014
Journal of Natural Products · 2016 · Q1 · FWCI 650.22 · 5,873 citations
Natural products remain a vital source for new drug discovery, with 49% of approved anti-cancer small molecules and a significant portion of anti-infectives derived from or directly based on natural compounds between 1981 and 2014.
The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises
Pain · 2020 · Q1 · SJR 2.00 · FWCI 325.91 · 4,928 citations
The IASP has revised its 40-year-old definition of pain to "An unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage," updating accompanying notes to clarify concepts.
Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010
Journal of Natural Products · 2012 · Q1 · FWCI 395.44 · 4,679 citations
Natural products remain a vital source for novel drug structures, with 48.6% of anti-cancer small molecules and a significant portion of anti-infectives derived from them between 1981-2010.
Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis
The Lancet · 2018 · FWCI 67.49 · 3,496 citations · Open access
A comprehensive meta-analysis of 522 trials found that while all 21 antidepressants studied were more effective than placebo for acute major depressive disorder, differences in efficacy and acceptability varied significantly, particularly in head-to-head comparisons.
European Guidelines for Obesity Management in Adults
Obesity Facts · 2015 · Q1 · SJR 1.00 · FWCI 222.77 · 3,396 citations · Open access
New European guidelines emphasize obesity as a chronic disease requiring lifelong, multidisciplinary management, integrating diet, exercise, behavioral therapy, pharmacotherapy, and surgery.
Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)
Pain · 2018 · Q1 · SJR 2.00 · FWCI 106.66 · 3,308 citations
A new classification system for chronic pain, applicable across diverse settings, defines chronic pain as lasting over 3 months and categorizes it as either "chronic primary pain" (a disease in itself) or "chronic secondary pain" (a symptom of another disease).
Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine · 2017 · Q1 · SJR 2.00 · FWCI 198.07 · 3,257 citations
For acute/subacute low back pain, nonpharmacologic treatments like heat, massage, or acupuncture are recommended first, with NSAIDs or muscle relaxants if medication is needed. For chronic low back pain, exercise and other nonpharmacologic therapies are the initial choice.
The global burden of low back pain: estimates from the Global Burden of Disease 2010 study
Annals of the Rheumatic Diseases · 2014 · Q1 · SJR 7.00 · FWCI 153.73 · 3,230 citations · Open access
Low back pain (LBP) is the leading cause of disability globally, ranking highest among 291 conditions studied for disability (YLDs) and sixth for overall burden (DALYs). Its global burden has significantly increased from 1990 to 2010.
antiSMASH 5.0: updates to the secondary metabolite genome mining pipeline
Nucleic Acids Research · 2019 · Q1 · SJR 8.00 · FWCI 355.67 · 3,133 citations · Open access
The antiSMASH 5.0 pipeline, a widely used tool for identifying microbial biosynthetic gene clusters, has been significantly updated with new detection rules for diverse secondary metabolites and improved analysis speed.
A systematic review of the global prevalence of low back pain
Arthritis & Rheumatism · 2012 · FWCI 24.95 · 3,019 citations
A systematic review of 165 studies found that low back pain is a major global health issue, with an estimated point prevalence of 11.9% and a 1-month prevalence of 23.2%.
Adverse Health Effects of Marijuana Use
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 184.81 · 2,762 citations
Contrary to popular belief, marijuana use may pose significant health risks, despite its increasing legalization and perceived harmlessness.
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Molecules · 2020 · Q1 · FWCI 136.59 · 2,686 citations · Open access
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder leading to dementia, with current treatments only managing symptoms, not curing or preventing the disease.
Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016
MMWR Morbidity and Mortality Weekly Report · 2018 · Q1 · SJR 8.00 · FWCI 142.80 · 2,625 citations
In 2016, an estimated 20.4% (50 million) of U.S. adults experienced chronic pain, with 8.0% (19.6 million) suffering from high-impact chronic pain that frequently limits daily activities.
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Current Neuropharmacology · 2013 · Q1 · SJR 1.00 · FWCI 54.34 · 2,556 citations · Open access
Acetylcholinesterase inhibitors, by blocking the breakdown of acetylcholine, are used therapeutically for neurodegenerative diseases and also act as toxins. This review details their pharmacology and toxicology, covering both reversible and irreversible types.
Antibiotics: past, present and future
Current Opinion in Microbiology · 2019 · Q1 · SJR 2.00 · FWCI 98.97 · 2,346 citations
Antibiotic discovery, which dramatically extended human lifespan, has declined since the mid-1950s, leading to a current antimicrobial resistance crisis.
RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH
Journal of Pain & Palliative Care Pharmacotherapy · 2012 · Q3 · FWCI 185.76 · 2,208 citations
A comprehensive report from the National Academy of Sciences (via the Institute of Medicine) outlines a national blueprint to transform pain prevention, care, education, and research in America.
Taxonomy, Physiology, and Natural Products of Actinobacteria
Microbiology and Molecular Biology Reviews · 2016 · Q1 · SJR 3.00 · FWCI 122.50 · 2,197 citations · Open access
Actinobacteria are a vast and diverse phylum of Gram-positive bacteria crucial for biotechnology and medicine, producing approximately two-thirds of all naturally derived antibiotics and many other valuable compounds.
Cognitive impairment in depression: a systematic review and meta-analysis
Psychological Medicine · 2013 · Q1 · SJR 2.00 · FWCI 10.41 · 2,168 citations
Cognitive deficits in executive function, memory, and attention are core features of depression, persisting even after depressive symptoms remit.
Recently added
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
The Lancet Rheumatology · 2023 · Q1 · SJR 6.00 · FWCI 301.13 · 1,570 citations · Open access
In 2020, low back pain affected 619 million people globally, with projections indicating 843 million cases by 2050, despite a modest 10.4% decrease in age-standardized prevalence rates since 1990.
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Molecules · 2020 · Q1 · FWCI 136.59 · 2,686 citations · Open access
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder leading to dementia, with current treatments only managing symptoms, not curing or preventing the disease.
Important Flavonoids and Their Role as a Therapeutic Agent
Molecules · 2020 · Q1 · FWCI 78.67 · 1,628 citations · Open access
Flavonoids, plant-derived compounds found in fruits and vegetables, exhibit significant anticancer, antioxidant, anti-inflammatory, antiviral, neuroprotective, and cardio-protective effects, with their biological activity dependent on type, mode of action, and bioavailability.
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease
Neuropharmacology · 2020 · Q1 · SJR 1.00 · FWCI 56.76 · 1,089 citations
Current acetylcholinesterase inhibitors (ChE-Is) for Alzheimer's disease (AD) offer mild, potentially not clinically significant benefits, with similar efficacy across available drugs like donepezil, rivastigmine, and galantamine.
Obesity in adults: a clinical practice guideline
Canadian Medical Association Journal · 2020 · Q2 · FWCI 98.26 · 1,456 citations · Open access
Obesity is a complex chronic disease characterized by excess body fat that impairs health, increases medical risks, and reduces lifespan, with severe obesity increasing more than fourfold globally.
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app